Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2022 Filed Sep 30, 2022 20:44 UTC |
HALAS GUS DDirector
|
Exercise / conversionCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025810 · wf-form4_166457066314869.xml · nonDerivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:37 UTC |
Vos Ellen O'ConnorDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025807 · wf-form4_166457022239063.xml · derivative · entry 2 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On September 29, 2021 the reporting person was granted 334 restricted stock units which vested in full on September 29, 2022. F2 · derivative.expiration_date: On September 29, 2021 the reporting person was granted 334 restricted stock units which vested in full on September 29, 2022. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:37 UTC |
Vos Ellen O'ConnorDirector
|
Exercise / conversionCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025807 · wf-form4_166457022239063.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 26, 2022 Filed Aug 30, 2022 20:45 UTC |
Odence-Ford MarionGeneral Counsel and CCO
|
PurchaseCommon Stock | 1,000 | $15.75 | $15,750.00 |
DisclosureSEC source: 0001213900-22-052320 · ownership.xml · nonDerivative · entry 1 Odence-Ford Marion · CIK 0001845002 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:45 UTC |
FEBBO WILLIAM JDirector · CEO
|
PurchaseCommon Stock | 10,700 | $15.29 | $163,641.52 |
DisclosureSEC source: 0001213900-22-050555 · ownership.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,772 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.19 to $15.43. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:45 UTC |
Lang James PaulDirector
|
PurchaseCommon Stock | 6,000 | $16.45 | $98,723.40 |
DisclosureSEC source: 0001213900-22-050556 · ownership.xml · nonDerivative · entry 1 Lang James Paul · CIK 0001703090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,660 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.415 to $16.47. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:45 UTC |
FEBBO WILLIAM JDirector · CEO
|
PurchaseCommon Stock | 5,400 | $16.18 | $87,363.90 |
DisclosureSEC source: 0001213900-22-050555 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,072 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.13 to $16.24. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:46 UTC | PurchaseCommon Stock | 3,200 | $15.66 | $50,112.00 |
DisclosureSEC source: 0001213900-22-049032 · ownership.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Read SEC document |
|
| August 16, 2022 Filed Aug 17, 2022 20:45 UTC |
Vos Ellen O'ConnorDirector
|
PurchaseCommon Stock | 500 | $15.91 | $7,955.00 |
DisclosureSEC source: 0001213900-22-049031 · ownership.xml · nonDerivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:45 UTC |
Stelmakh EdwardCFO/COO
|
PurchaseCommon Stock | 3,000 | $15.43 | $46,290.00 |
DisclosureSEC source: 0001213900-22-049030 · ownership.xml · nonDerivative · entry 1 Stelmakh Edward · CIK 0001887046 · CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:45 UTC |
Vos Ellen O'ConnorDirector
|
GrantRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-032532 · ownership.xml · derivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637 Underlying: Common Stock · 4,637 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F2 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:45 UTC |
Spangler Patrick DDirector
|
GrantRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-032531 · ownership.xml · derivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637 Underlying: Common Stock · 4,637 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F2 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:45 UTC |
Lang James PaulDirector
|
GrantRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-032530 · ownership.xml · derivative · entry 1 Lang James Paul · CIK 0001703090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637 Underlying: Common Stock · 4,637 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F2 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:45 UTC |
HALAS GUS DDirector
|
GrantRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-032529 · ownership.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637 Underlying: Common Stock · 4,637 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F2 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:45 UTC |
WASSON GREGORY DDirector
|
GrantRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-032528 · ownership.xml · derivative · entry 1 WASSON GREGORY D · CIK 0001188827 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637 Underlying: Common Stock · 4,637 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F2 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:48 UTC |
Spangler Patrick DDirector
|
GrantRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-017502 · ownership.xml · derivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest on March 30, 2023. F2 · derivative.expiration_date: The restricted stock units vest on March 30, 2023. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:48 UTC |
Lang James PaulDirector
|
GrantRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-017501 · ownership.xml · derivative · entry 1 Lang James Paul · CIK 0001703090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest on March 30, 2023. F2 · derivative.expiration_date: The restricted stock units vest on March 30, 2023. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:47 UTC |
HALAS GUS DDirector
|
GrantRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-017500 · ownership.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest on March 30, 2023. F2 · derivative.expiration_date: The restricted stock units vest on March 30, 2023. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:45 UTC |
WASSON GREGORY DDirector
|
GrantRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-017498 · ownership.xml · derivative · entry 1 WASSON GREGORY D · CIK 0001188827 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest on March 30, 2023. F2 · derivative.expiration_date: The restricted stock units vest on March 30, 2023. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:46 UTC |
Vos Ellen O'ConnorDirector
|
GrantRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-017499 · ownership.xml · derivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest on March 30, 2023. F2 · derivative.expiration_date: The restricted stock units vest on March 30, 2023. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:45 UTC |
Odence-Ford MarionGeneral Counsel and CCO
|
GrantRestricted Stock Units · Derivative | 2,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-010597 · ownership.xml · derivative · entry 2 Odence-Ford Marion · CIK 0001845002 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,313 Underlying: Common Stock · 2,313 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:45 UTC |
Odence-Ford MarionGeneral Counsel and CCO
|
GrantStock Option · Derivative | 4,690 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001213900-22-010597 · ownership.xml · derivative · entry 1 Odence-Ford Marion · CIK 0001845002 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,690 Underlying: Common Stock · 4,690 shares Expires 2027-03-01 F1 · derivative.exercise_date: The stock option vests in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:46 UTC |
Inman ToddChief Technology Officer
|
GrantRestricted Stock Units · Derivative | 2,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-010598 · ownership.xml · derivative · entry 2 Inman Todd · CIK 0001858241 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,313 Underlying: Common Stock · 2,313 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:46 UTC |
Inman ToddChief Technology Officer
|
GrantStock Option · Derivative | 4,690 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001213900-22-010598 · ownership.xml · derivative · entry 1 Inman Todd · CIK 0001858241 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,690 Underlying: Common Stock · 4,690 shares Expires 2027-03-01 F1 · derivative.exercise_date: The stock option vests in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:46 UTC |
Silvestro Stephen LChief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 5,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-010599 · ownership.xml · derivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,782 Underlying: Common Stock · 5,782 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:46 UTC |
Silvestro Stephen LChief Commercial Officer
|
GrantStock Option · Derivative | 11,726 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001213900-22-010599 · ownership.xml · derivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,726 Underlying: Common Stock · 11,726 shares Expires 2027-03-01 F1 · derivative.exercise_date: The stock option vests in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock | 400 | $44.96 | $17,984.00 |
DisclosureSEC source: 0001213900-22-008987 · ownership.xml · nonDerivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,672 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.93 to $44.97. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock | 7,066 | $44.12 | $311,766.05 |
DisclosureSEC source: 0001213900-22-008987 · ownership.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,072 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock | 9,200 | $43.38 | $399,086.80 |
DisclosureSEC source: 0001213900-22-008987 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,138 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.84 to $43.83. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:45 UTC |
Odence-Ford MarionGeneral Counsel and CCO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-007910 · ownership.xml · derivative · entry 2 Odence-Ford Marion · CIK 0001845002 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 11, 2021, the reporting person was granted 20,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date F2 · derivative.expiration_date: On February 11, 2021, the reporting person was granted 20,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:45 UTC |
Odence-Ford MarionGeneral Counsel and CCO
|
Exercise / conversionCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-007910 · ownership.xml · nonDerivative · entry 1 Odence-Ford Marion · CIK 0001845002 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock | 300 | $48.52 | $14,556.90 |
DisclosureSEC source: 0001213900-22-002854 · ownership.xml · nonDerivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,338 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.385 to $48.80. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock | 8,226 | $47.57 | $391,327.27 |
DisclosureSEC source: 0001213900-22-002854 · ownership.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,638 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.29 to $48.18. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock | 8,140 | $46.92 | $381,888.10 |
DisclosureSEC source: 0001213900-22-002854 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,864 F1 · kind: The sales reported in this Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan, adopted on May 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $47.28. The reporting person undertakes to provide to OptimizeRx Corporation, any security holder of OptimizeRx Corporation or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
Tax withholdingUnvested Restricted Stock Award · Derivative | 9,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-001562 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,256 Underlying: Common Stock · 28,883 shares Expires 2024-01-07 F1 · derivative.exercise_price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. F1 · derivative.exercise_date: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
Tax withholdingCommon Stock | 9,627 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-001562 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,004 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:45 UTC |
WASSON GREGORY DDirector
|
GrantRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-000278 · ownership.xml · derivative · entry 1 WASSON GREGORY D · CIK 0001188827 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 Underlying: Common Stock · 409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:45 UTC |
Spangler Patrick DDirector
|
GrantRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-000275 · ownership.xml · derivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 Underlying: Common Stock · 409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:45 UTC |
HALAS GUS DDirector
|
GrantRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-000274 · ownership.xml · derivative · entry 1 HALAS GUS D · CIK 0001230322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 Underlying: Common Stock · 409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:45 UTC |
Vos Ellen O'ConnorDirector
|
GrantRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-000277 · ownership.xml · derivative · entry 1 Vos Ellen O'Connor · CIK 0001534357 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 Underlying: Common Stock · 409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:45 UTC |
Lang James PaulDirector
|
GrantRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-000276 · ownership.xml · derivative · entry 1 Lang James Paul · CIK 0001703090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 Underlying: Common Stock · 409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:45 UTC |
Silvestro Stephen LCHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option · Derivative | 13,241 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001213900-21-066731 · ownership.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,511 Underlying: Common Stock · 13,241 shares Expires 2025-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:45 UTC |
Silvestro Stephen LCHIEF COMMERCIAL OFFICER
|
SaleCommon Stock pursuant to 10B5-1 plan | 13,241 | $54.87 | $726,533.67 |
DisclosureSEC source: 0001213900-21-066731 · ownership.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: These shares sold pursuant to a plan of disposition adopted on March 11, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:45 UTC |
Silvestro Stephen LCHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 13,241 | $7.51 | $99,439.91 |
DisclosureSEC source: 0001213900-21-066731 · ownership.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:45 UTC |
FEBBO WILLIAM JDirector · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock (pursuant to 10B5-1 plan) | 16,666 | $54.55 | $909,130.30 |
DisclosureSEC source: 0001213900-21-066031 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,377 F1 · security: These shares sold pursuant to a plan of disposition adopted on May 28, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 21:45 UTC |
Paramore Miriam JPRESIDENT AND CSO
|
Exercise / conversionStock Option · Derivative | 3,558 | $7.51 Strike: $7.51 | $26,720.58 |
DisclosureSEC source: 0001213900-21-063363 · ownership.xml · derivative · entry 3 Paramore Miriam J · CIK 0001713156 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,760 Underlying: Common Stock · 3,558 shares Expires 2025-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 21:45 UTC |
Paramore Miriam JPRESIDENT AND CSO
|
Exercise / conversionCommon Stock | 3,558 | $7.51 | $26,720.58 |
DisclosureSEC source: 0001213900-21-063363 · ownership.xml · nonDerivative · entry 2 Paramore Miriam J · CIK 0001713156 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 21:45 UTC |
Paramore Miriam JPRESIDENT AND CSO
|
SaleCommon Stock Pursuant to 10B5-1 Plan | 3,558 | $61.48 | $218,745.84 |
DisclosureSEC source: 0001213900-21-063363 · ownership.xml · nonDerivative · entry 1 Paramore Miriam J · CIK 0001713156 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,049 F1 · security: These shares sold pursuant to a plan of disposition adopted on March 24, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:45 UTC |
Silvestro Stephen LCHIEF COMMERCIAL OFFICER
|
Exercise / conversionStock Option · Derivative | 13,241 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001213900-21-060876 · ownership.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,752 Underlying: Common Stock · 13,241 shares Expires 2025-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:45 UTC |
Silvestro Stephen LCHIEF COMMERCIAL OFFICER
|
SaleCommon Stock pursuant to 10B5-1 plan | 13,241 | $73.98 | $979,569.18 |
DisclosureSEC source: 0001213900-21-060876 · ownership.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: These shares sold pursuant to a plan of disposition adopted on March 11, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.